BidaskClub lowered shares of Audentes Therapeutics (NASDAQ:BOLD) from a buy rating to a hold rating in a report issued on Friday morning.
Several other brokerages have also recently weighed in on BOLD. Cowen initiated coverage on Audentes Therapeutics in a report on Friday, September 7th. They issued a sell rating and a $20.00 price objective for the company. Mizuho restated a buy rating and issued a $45.00 price objective on shares of Audentes Therapeutics in a report on Wednesday, August 22nd. HC Wainwright set a $40.00 price objective on Audentes Therapeutics and gave the company a buy rating in a report on Wednesday, August 8th. Citigroup initiated coverage on Audentes Therapeutics in a report on Monday, August 20th. They issued a neutral rating and a $40.00 price objective for the company. Finally, Raymond James restated a hold rating on shares of Audentes Therapeutics in a report on Wednesday, August 8th. Two equities research analysts have rated the stock with a sell rating, five have assigned a hold rating and seven have given a buy rating to the company’s stock. The company has a consensus rating of Hold and a consensus price target of $36.45.
BOLD opened at $36.64 on Friday. Audentes Therapeutics has a 1 year low of $24.32 and a 1 year high of $46.18. The stock has a market capitalization of $1.48 billion, a price-to-earnings ratio of -10.78 and a beta of 0.73.
Audentes Therapeutics (NASDAQ:BOLD) last released its quarterly earnings results on Wednesday, August 8th. The biotechnology company reported ($0.85) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.78) by ($0.07). Equities research analysts forecast that Audentes Therapeutics will post -3.33 earnings per share for the current fiscal year.
In related news, VP Suyash Prasad sold 10,000 shares of Audentes Therapeutics stock in a transaction dated Monday, October 1st. The stock was sold at an average price of $36.88, for a total transaction of $368,800.00. Following the completion of the transaction, the vice president now owns 100 shares in the company, valued at $3,688. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Matthew R. Patterson sold 12,952 shares of Audentes Therapeutics stock in a transaction dated Tuesday, September 18th. The stock was sold at an average price of $40.00, for a total value of $518,080.00. Following the transaction, the chief executive officer now owns 12,952 shares of the company’s stock, valued at approximately $518,080. The disclosure for this sale can be found here. Insiders sold a total of 77,039 shares of company stock valued at $2,925,260 in the last 90 days. 6.60% of the stock is owned by corporate insiders.
A number of institutional investors have recently bought and sold shares of the stock. Northern Trust Corp grew its holdings in Audentes Therapeutics by 48.0% during the second quarter. Northern Trust Corp now owns 368,571 shares of the biotechnology company’s stock worth $14,083,000 after purchasing an additional 119,602 shares during the period. Bank of New York Mellon Corp grew its holdings in Audentes Therapeutics by 32.1% during the second quarter. Bank of New York Mellon Corp now owns 127,693 shares of the biotechnology company’s stock worth $4,879,000 after purchasing an additional 31,048 shares during the period. Cowen Inc. bought a new position in Audentes Therapeutics during the second quarter worth about $3,057,000. California Public Employees Retirement System grew its holdings in Audentes Therapeutics by 311.6% during the second quarter. California Public Employees Retirement System now owns 44,057 shares of the biotechnology company’s stock worth $1,683,000 after purchasing an additional 33,352 shares during the period. Finally, Millennium Management LLC grew its holdings in Audentes Therapeutics by 59.5% during the second quarter. Millennium Management LLC now owns 337,055 shares of the biotechnology company’s stock worth $12,879,000 after purchasing an additional 125,707 shares during the period. Institutional investors and hedge funds own 96.74% of the company’s stock.
Audentes Therapeutics Company Profile
Audentes Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing gene therapy products for patients suffering from diseases caused by single gene defects. The company is developing AT132, which is in Phase I/II clinical studies for the treatment of X-linked myotubular myopathy (XLMTM); AT342 that is in Phase I/II clinical studies to treat crigler-najjar syndrome; AT982, which is in preclinical studies for the treatment of pompe disease; and AT307 that is in preclinical studies to treat CASQ2 subtype of catecholaminergic polymorphic ventricular tachycardia.
Receive News & Ratings for Audentes Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Audentes Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.